CDKN2A and nasopharyngeal carcinoma: The detection rate of methylated CDKN2A products in NPC groups ranges from 22% to 67%, DAPK1 from 20% to 89%, and RASSF1A from 29% to 91%, indicating substantial heterogeneity among samples from different sources [10,11,23–34].